Onco Wiki / Enfermedad

Carcinoma de células basales (BCC)

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDDIS-BCC
TipoEnfermedad
Aliaces
BCCCarcinoma de células basalescáncer de piel de células basalesBasaliomaúlcera de roedoresБазально-клітинна карцинома (БКК)
Situaciónreviewed 2026-05-04 | pending_clinical_signoff
EnfermedadesNinguna declarada
FuentesSRC-NCCN-MELANOMA-2025 SRC-NCCN-SKIN-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Fuente YAML

icd_o_3_morphology8090/3
icd_o_3_topography["C44"]
icd_10C44
who_classificationWHO Classification of Skin Tumours 5th ed (2023): Basal cell carcinoma

Capacidades

Notas

The vast majority of BCCs are cured with surgery or radiation. Hedgehog inhibitors (vismodegib, sonidegib) are approved only for locally advanced unresectable or metastatic BCC — a small fraction of all BCCs. Gorlin syndrome (PTCH1 germline) warrants genetic counseling and lifelong surveillance. SMO inhibitors cause significant side effects (muscle cramps, alopecia, dysgeusia, weight loss) limiting long-term use. Cemiplimab (anti-PD-1) is FDA-approved for locally advanced/metastatic BCC after HHI failure.

Utilizado por

Relevancia terapéutica

Algoritmos

Indicación

Cuestionarios

Señal de alerta